Prof. Dr. med. Marion Subklewe

 

Professional Experience
since 2017 Head of the Laboratory for Translational Cancer Immunology,
Gene Center Munich
since 2014 Professor for Internal Medicine
with focus on Cellular Immunotherapy
2012-2017 Head of the Clinical Cooperation Group "Immunotherapy",
Helmholtz Zentrum Munich
since 2009 Head of Flow Cytometry, Laboratory of Leukemia Diagnostics,
Klinikum - University of Munich, Medical Department III, 
Prof. Dr. W. Hiddemann
since 2009 Attending Physician for Hematology / Oncology
Klinikum - University of Munich, Medical Department III,
Prof. Dr. W. Hiddemann
2008-2009 Clinical Fellow Hematology / Oncology
Klinikum - University of Munich, Medical Department III,
Prof. Dr. W. Hiddemann
2000-2007 Clinical Fellow Hematology / Oncology
Charité - Campus Virchow Klinikum, Medical Department III,
Prof. Dr. B. Dörken
1996-2000 Postdoctoral Fellow, DFG-Scholarship, Cure for Lymphoma Fellow,
Rockefeller Univeristy, New York - Prof. Dr. R. M. Steinman
1995-1996 Residency Internal Medicine, University Hospital Tübingen,
Medical Department II, Hematology / Oncology / Reheumatology,
Prof. Dr. L. Kanz

 

Education
2014 W2-Professor for Internal Medicine with focus on Cellular Immunotherapy
2007 „Habilitation“ in Internal Medicine at the Charité, Berlin
2007 Board Certification Hematology / Oncology
2005 Board Certification Internal Medicine
1995 Medical Dissertation at the University of Cologne, Department of Internal Medicine, Hematology / Oncology, Prof. Dr. V. Diehl
1988-1993 Study of Medicine at the University of Cologne
1986-1988 Study of Medicine at the RWTH Aachen

 

Awards & honors
2015 M4-Award: Startup support for the development of a novel multispecific antibody derivative
2015 ASH Abstract Achievement Award: Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE Antibody Construct (AMG 330) Mediated Cytotoxicity
2014 DGHO-Poster Prize: Addition of CD200 and Omission of sIgM Improves the Scoring System for the Diagnosis of CLL
2013 Selection for the ASH Highlights: Evaluation of CD33 expression and functional analysis of the CD33/CD3 bispecific antibody AMG 330 activity in primary AML samples
2012 Therese von Bayern-Award
2011 ASH Abstract Achievement Award: A Combined Score of Minimal Residual Disease (MRD) Assessment by Flow Cytometry, Cytogenetic and Molecular Markers As Well As Age Predicts Outcome and Can Potentially Guide MRD-Based Therapy in Acute Myeloid Leukemia
2011 ASH Abstract Achievement Award: Dendritic Cells Matured with a TLR7/8 Agonist Induce T Helper 1 Cell Polarization, Activate NK Cells and Are Thus Highly Suitable for Application in Cancer Immunotherapy
2011 Best Lecturer at the faculty of Medicine at the LMU
2005-2007 Rahel-Hirsch Scholarship at the Charité („Habilitations-Scholarship“)
1999-2000 Cure for Lymphoma Foundation Fellow
1996-1999 Postdoctoral Scholarship of the Deutsche Forschungsgemeinschaft

 

Additional functions
Spokesman of the Else Kröner Clinician Scientist Programm Cancer Immunotherapy - LMU Munich, fostering the development of clinician scientists in oncology/immunology by a network of expert mentors, protected time for research, seminars and travel support

Principal Investigator and Sponsor delegated Person of a prospective Phase I/II I-IT “Active immunotherapy of patients with AML using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens”

Principal Investigator of a Phase I Study „A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia“

Principle Investigator in multiple Phase I trials (CAR T, T-cell recruiting antibodies), Principle Investigator in multiple Phase II/III trials in leukemia and lymphoma (GMALL, GLSG, DSHNHL)

Protocol committee AML Cooperative Group (AML-CG)

Member of the Organizing Committee of the International Symposium “Acute Leukemias” 2011; 2013; 2015; 2017

Certification (2011) and Akkreditation Flow Cytometry (2012) within the Laboratory of Leukemia Diagnostics

Collaborative Research Activities – Bavarian Immunotherapy Network, Helmholtz Alliance for Immunotherapy, Deutsches Konsortium für Translationale Krebsforschung, Munich Immunotherapy Consortium (MITC), Elitenetzwerk Bayern International Graduate School “Immunotargeting of Cancer”, SFB1243 “Cancer Evolution”, Else-Kröner Fresenius Forschungskolleg “Cancer Immunotherapy”

Grant Reviews - Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; José-Carreras Stiftung; Wilhelm Sander Stiftung; Cancer Research UK; Leukemia and Lymphoma; OeGHO, Dutch Cancer Society, Wordwide Cancer Research

Manuscript Reviews - Blood, Leukemia, Lancet Hematology, NEJM, PlosOne, J International Immunology, Journal of Hematology & Oncology; Haematologica; British Journal of Hematology

Membership - Bund deutscher Internisten (BdI); European Association for Hematology (EHA); American Society for Hematology (ASH); Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO); Society for Immunotherapy of Cancer (SITC)

Member of the “Research committee (Forschungskommission)” Klinikum der Universität München, member of several Thesis Advisory Committees

  • -